Cargando…

Immunotherapy as a treatment for small cell lung cancer: a case report and brief review

Small cell lung cancer (SCLC), an aggressive disease characterized by rapid progression, early relapse and widespread metastasis, accounts for about 13–15% of lung cancer cases. Despite its initial sensitivity to chemotherapy and radiotherapy, SCLC commonly develops resistance to these treatments an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yan, Liu, Yu, Sun, Chenglong, Wang, Hao, Zhao, Sha, Li, Wei, Chen, Bin, Wang, Lei, Ye, Lingyun, He, Yayi, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225158/ https://www.ncbi.nlm.nih.gov/pubmed/32420081 http://dx.doi.org/10.21037/tlcr.2020.03.20

Ejemplares similares

CD137, an attractive candidate for the immunotherapy of lung cancer
por: Ye, Lingyun, et al.
Publicado: (2020)

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
por: Sun, Chenglong, et al.
Publicado: (2020)

Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
por: Guo, Haoyue, et al.
Publicado: (2020)

cGAS-STING, an important pathway in cancer immunotherapy
por: Jiang, Minlin, et al.
Publicado: (2020)

YAP1 expression is associated with survival and immunosuppression in small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2023)

Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure
por: Chen, Peixin, et al.
Publicado: (2020)

sLAG-3 in non-small-cell lung cancer patients’ serum
por: He, Yayi, et al.
Publicado: (2018)

Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review
por: Li, Wei, et al.
Publicado: (2020)

Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review
por: Chen, Shen, et al.
Publicado: (2019)

CD39: the potential target in small cell lung cancer
por: Chen, Shanhao, et al.
Publicado: (2020)

Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
por: Chen, Yu, et al.
Publicado: (2021)

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment
por: Wang, Hao, et al.
Publicado: (2019)

Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
por: Jiang, Minlin, et al.
Publicado: (2021)

Killer immunoglobulin-like receptors/human leukocyte antigen class-I, a crucial immune pathway in cancer
por: Xu, Yi, et al.
Publicado: (2020)

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2021)

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review
por: Liu, Yu, et al.
Publicado: (2021)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

Distinct patterns of somatic genomic alterations and mutational signatures in central and peripheral-type small-cell lung cancer
por: Wang, Lei, et al.
Publicado: (2021)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III
por: Jiang, Minlin, et al.
Publicado: (2021)

The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review
por: Song, Xinyu, et al.
Publicado: (2021)

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer
por: He, Yayi, et al.
Publicado: (2016)

Alterations of DNA damage repair in cancer: from mechanisms to applications
por: Jiang, Minlin, et al.
Publicado: (2020)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Wang, Haowei, et al.
Publicado: (2022)

Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor
por: Fang, Qiyu, et al.
Publicado: (2022)

Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer
por: Nyein, Andrew F., et al.
Publicado: (2022)

Percutaneous Microwave Coagulation Therapy: A Promising Therapeutic Method for Breaking the Barrier of the Intertumor Heterogeneity
por: Guo, Haoyue, et al.
Publicado: (2021)

The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection
por: Shi, Jinpeng, et al.
Publicado: (2021)

Single-Cell Sequencing, an Advanced Technology in Lung Cancer Research
por: Wang, Hao, et al.
Publicado: (2021)

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
por: He, Yayi, et al.
Publicado: (2017)

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer
por: Dai, Jiawei, et al.
Publicado: (2021)

Challenges and countermeasures of thoracic oncology in the epidemic of COVID-19
por: Guo, Haoyue, et al.
Publicado: (2020)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse
por: Guo, Haoyue, et al.
Publicado: (2021)

Risk factors for nicotine dependence in Chinese patients with lung cancer
por: Gu, Fen, et al.
Publicado: (2018)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non‐small cell lung cancer
por: Cheng, Lei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1q9etgfqq6mqa5kpnm21l1bn1u